HC Wainwright reaffirmed their buy rating on shares of Mind Medicine (MindMed) (NASDAQ:MNMD – Free Report) in a research ...

Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) had its price target decreased by investment analysts at Robert W.

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

(NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth ...

The company has begun testing its LSD-based anxiety treatment in late-stage trials as it builds toward potential FDA approval ...

Mind Medicine Inc. ( ($MNMD) ) has released its Q4 earnings. Here is a breakdown of the information Mind Medicine Inc. presented to its investors.

Mind Medicine (MindMed) Inc. ( NASDAQ: MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin - CMO ...

(NASDAQ: MNMD), (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth quarter ...

周五，研究机构H.C. Wainwright维持了对专注于开发精神健康疾病治疗方案的临床阶段生物制药公司MindMed（NASDAQ:MNMD）的买入评级和55.00美元的目标价。目前该股交易价格为6.61美元，分析师们认为具有显著上涨空间，他们的目标价区间在16美元至55美元之间。该机构分析师强调，即将到来的三期临床试验结果将成为推动股价达到其目标价的潜在催化剂。根据InvestingPro数据 ...